Note 8 – Other Non-Current Assets

million CHF

 

Notes

 

2018

 

12017

1

Restated to reflect adoption of IFRS 15 (see note 1)

 

 

 

 

 

 

 

Contingent consideration from disposal of Peptides business

 

5.4

 

31

 

40

Capitalized contract costs

 

3

 

31

 

31

Investments in associates / joint ventures

 

9

 

10

 

20

Other investments

 

 

 

12

 

16

Defined benefit pension plan asset

 

24.1

 

7

 

4

Loans and advances

 

 

 

46

 

5

Other assets

 

 

 

16

 

23

Total

 

 

 

153

 

139

«Loans and advances» includes with CHF 44 million the loan to BioAtrium AG. This company is a strategic partnership between Sanofi and Lonza (see note 9).